Comorbidities and Malignancy among NAFLD Patients Compared to the General Population, A Nation-Based Study

Area of Science:

• Hepatology
• Epidemiology
• Oncology

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition affecting liver health globally.
• Understanding the associated health risks, including comorbidities and malignancies, is crucial for patient management.
• This study addresses the need for comparative data on NAFLD patient outcomes versus the general population.

Purpose of the Study:

• To investigate the frequency of comorbidities and malignancies in patients diagnosed with NAFLD.
• To compare these frequencies against a matched cohort from the general population.
• To analyze all-cause mortality rates between NAFLD patients and controls.

Main Methods:

• Retrospective analysis of adult patients with NAFLD.
• Inclusion of a control group matched for age and gender.
• Collection and comparison of demographic data, comorbidities, malignancies, and mortality.

Main Results:

• 211,955 NAFLD patients were compared to 452,012 controls.
• NAFLD patients showed significantly higher rates of diabetes, obesity, hypertension, ischemic heart disease, and CVA.
• Elevated rates of prostate, breast, colorectal, uterine, and kidney cancers were observed in NAFLD patients, with lower rates of lung and stomach cancers.

Conclusions:

• NAFLD is associated with increased prevalence of significant comorbidities.
• Patients with NAFLD demonstrate a higher incidence of specific malignancies.
• Despite associated health risks, NAFLD patients exhibited a lower all-cause mortality rate compared to the general population.